Background and aims Metronidazole, a commonly used antibiotic drug, can cause adverse effects in the central nervous system termed metronidazole-induced encephalopathy, leading to diagnostic challenges. The condition is rare and a detailed description of its phenotype is lacking. In this systematic review we investigated the clinical features of metronidazoleinduced encephalopathy to promote recognition and elaborate the description. Methods We performed a systematic literature search using PubMed.gov and hand searched the reference lists of included articles and other publications of interest. We included case series and single reports describing individual patients developing symptoms from the central nervous system in relation to metronidazole treatment. Data were extracted and analyzed descriptively.
Introduction
Global use of antibiotics is rising including non-prescription consumption [1, 2] , and thus, the potential for adverse effects is substantial. Neurological adverse effects following antibiotics are probably underdiagnosed [3] and must be addressed.
Metronidazole is a 5-nitroimidazole antibiotic used extensively worldwide against anaerobic and parasitic infections due to its efficacy and safety [4] . In rare cases, neurological adverse effects have been described, typically as a polyneuropathy [5] . Adverse effects of metronidazole on the central nervous system (CNS) cause metronidazole-induced encephalopathy (MIE), typically presenting with cerebellar and brainstem deficits, encephalopathy and occasionally seizures. Due to its rarity, clinical suspicion may not rise at first, hence the diagnosis is often delayed, potentially resulting in serious complications.
We have conducted this systematic review to promote recognition and diagnosis of MIE by updating and elaborating the description.
Methods

Reporting
This systematic review is based on case series and single reports. We have adhered to the concepts of the PRISMA guidelines where applicable [6] .
Search
The literature search was performed until September 24th, 2018 on PubMed.gov.
No filters were applied, and the following search terms were used:
Metronidazole AND (neurotoxicity OR encephalopathy OR coma OR consciousness OR (mental status) OR ataxia OR dyscoordination OR seizure OR (focal neurological deficit) OR dysarthria OR paralysis OR paresis OR palsy OR cerebral OR brain OR (central nervous system) OR (dentate nucleus) OR (dentate nuclei)).
Eligibility
No restrictions were made on the year of publication.
Only publications written in English were included. Any type of publication that contained at least one original case report was included.
Publications comprised human subjects of any age who developed symptoms from the central nervous system in relation to metronidazole treatment.
If patient data overlapped, we selected the original publication to avoid duplicate data.
Exclusions
Studies were excluded for the following reasons:
Data on several patients were pooled and not presented as individual cases.
The patient only experienced symptoms from the peripheral nervous system.
Cases where magnetic resonance imaging (MRI) was not performed on patients who only experienced symptoms outside our search definition.
Study selection
Results from the database search were transferred into a document making up one list of publications. Authors CGS and WKK independently screened the titles and abstracts for potentially relevant publications to assess in full text. Evident non-English publications were excluded at this point. Full text documents were evaluated according to the selection criteria described above. Finally, the reference lists of all included publications and other publications of interest were hand searched for additional relevant studies. Disagreements were discussed and in cases of doubt, the discussion was settled by authors CGS, WKK, FA, and ML, and it was always possible to reach an agreement.
Data extraction
We pilot-tested a predefined Excel sheet on five included case studies and revised it.
Data were extracted independently by authors CGS and WKK. Due to the inherent heterogeneity of case reports, the entire data set was later reviewed by authors CGS and WKK to ensure correct and comparable data.
Data items
Extracted data included article demographics, pre-existing conditions, time to onset of CNS symptoms, total treatment duration and accumulated dose of metronidazole, diagnostic methods, findings, and follow-up.
Treatment duration and accumulated dose were calculated or approximated, when not stated explicitly. In this context we defined a week as 7 days, a month as 30 days and a year as 365 days.
Some patients developed MIE more than once. When this occurred in relation to one disease course, the durations of treatment and accumulated doses were summated. If a patient developed MIE in relation to separate disease courses, the durations of treatment and accumulated dose from the first disease course were reported. In both cases, all symptoms and findings, including MRI, were reported to maximize the amount of data.
Analysis
Data were analyzed descriptively. Bias and study quality were not assessed formally. Figure 1 illustrates the process of identifying eligible case reports and series as a flow diagram.
Results
The literature search in PubMed produced 767 records. Based on the database search 107 publications were included. A further 5 publications were included by hand searching the reference lists of the included studies and other publications of interest. In total, our search yielded 112 publications comprising 136 patients .
See online supplementary file for a detailed list of all extracted data from the included cases.
Demographic information and clinical findings
MIE has been described worldwide, with most cases originating from the United States of America (24%), South Korea (21%), India (17%), and Japan (11%).
The population consisted of 65% males (n = 88) and 35% females (n = 48), making the ratio approximately 2:1.
Of the 136 cases, 130 were adults and the remaining 6 cases [15, 16, 23, 27, 63, 105] were below 18 years of age. The age spanned from a neonate [16] to 89 years [108] . The average age for adults was 56.8 years. Most patients (79%) were 40 years of age or above.
The presence or absence of pre-existing conditions was explicitly stated in 67% of cases (n = 91). Hepatic disease defined as cirrhosis, liver failure, and autoimmune hepatobiliary disease was reported in 15% of all cases (n = 20). Diabetes mellitus was present in 10% (n = 13). Chronic renal failure (n = 9), inflammatory bowel disease (n = 9) or active malignant disease (n = 9) was reported in 7% of cases, respectively. Since pre-existing conditions were not mentioned in 33% of cases (n = 45), the prevalence of these conditions is probably higher than mentioned above.
The indications for treatment were primarily anaerobic and parasitic infections and the daily doses were generally similar, although in some cases the dosing regimen was not in accordance with standard practice due to self-medication [66] or experimental medication aimed at increasing radiation sensitivity [41] . The most common indications were treatment or prophylaxis of gastrointestinal infections (38%), hepatic abscess (18%), and CNS infections (10%).
Total duration of treatment was reported or could be approximated from available data in 92% of cases (n = 125) and ranged from 2 days [12] to almost 8 years [95] . Due to outliers, duration of treatment averaged 101.6 days, with a lower quartile of 19.5 days, median of 35 days and upper quartile of 63 days. Duration of treatment was longer than 1 year in 3.9% (n = 5) [20, 24, 31, 95] .
Cumulative doses were available in 85% of adult cases (n = 110) and ranged from 5 [22] to 2000 g [24] , with an average of 125.7 g, a lower quartile of 36 g, a median of 65.4 g and upper quartile of 110.8 g.
Symptoms often presented in succession, but could also occur simultaneously. Duration of treatment before onset of the first symptoms from the central nervous system was available in 76% of cases (n = 104) with an average of 47.2 days, lower quartile of 14 days, median of 28 days and upper quartile of 52.5 days.
Symptoms and findings on neurological examination are illustrated in Fig. 2 . The details of symptoms and clinical findings reported varied considerably between studies and were therefore categorized. One patient was a neonate and therefore symptoms were not comparable.
MRI findings
Diagnostic MRI findings on T2-weighted and fluid-attenuated inverse recovery (FLAIR) sequences are illustrated in Fig. 3 . An example of typical MRI findings is shown in Fig. 4 .
Diagnostic MRIs were available in 91% of cases (n = 124). Hyperintense lesions of the dentate nuclei, almost invariably symmetric, were by far the most common lesions, seen in 90% (n = 112). Of the callosal lesions, the splenium was particularly susceptible (96%; n = 52).
Twelve patients did not develop lesions in the dentate nuclei on T2/FLAIR. Of these, eight patients had lesions in the corpus callosum [23, 31, 34, 70, 90, 95, 99] , one patient had lesions in the brainstem [57] and one patient had lesions in the cerebral white matter and cerebellar peduncles [46] . Only 2% (n = 2) of patients did not have acute changes on MRI [12, 63] .
Diffusion-weighted imaging (DWI) results were reported in 55% (n = 68) of cases containing diagnostic MRI, and apparent diffusion coefficient (ADC) reported in 32% (n = 40). DWI lesions were most frequently located in the corpus callosum (57%; n = 39), dentate nuclei (56%; n = 38), and the midbrain (29%; n = 20). Most DWI lesions in corpus callosum were correspondingly hypointense on ADC (79%), while only some DWI lesions in dentate nuclei were hypointense on ADC (33%).
A minority of cases reported highly unusual findings. Two cases [36, 42] reported in addition to typical MRI lesions, cystic necrosis of the corpus callosum bearing resemblance to Marchiafava-Bignami disease. In another case involving a 14-year old boy [105] , hyperintensities on T2 were seen in the cervical spinal cord in addition to more typical brain lesions.
Follow-up
Outcome was reported in 96% of all cases (n = 131). Resolution of CNS symptoms was reported in 56% (n = 73). A marked or dramatic improvement was reported in 19% (n = 25). Improvement without further specification was reported in 16% (n = 21), while improvement with remaining severe neurological deficits was reported in 4% (n = 5) [42, 66, 69, 90, 106] . Death was reported in 5% (n = 6) [22, 39, 46, 55, 57, 116] and one patient remained in a persistent vegetative state [66] . In adults, the cumulative dose averaged 155.1 g in the "resolution" group (n = 61), 90.9 g in the "marked/dramatic improvement" group (n = 19), 75.5 g in the "improvement unspecified" group (n = 19) and also 75.5 g in the group who had severe remaining deficits or expired (n = 9).
Symptoms consistent with polyneuropathy were present in 16% (n = 21) of all patients at follow-up.
Follow-up MRI was reported in 65% (n = 88), although 1 case was not clearly described [118] . Time from discontinuation of metronidazole to follow-up MRI was available in 79 patients and spanned from 3 days [26, 79] to one and a half year [107] with a median of 34 days. Resolution was observed in 64% patients (n = 56), near-complete resolution in 15% (n = 13), improvement in 17% (n = 15), minor changes in 2% (n = 2), and no change in 1% (n = 1).
Discussion
This systematic review identified 112 publications comprising 136 unique cases of metronidazole-induced encephalopathy. The most common clinical manifestations were dysarthria, limb dyscoordination, gait instability and altered consciousness. MRI showed characteristic hyperintense lesions on T2-weighted and FLAIR in the dentate nuclei in 90% of cases. Lesions were also common in the splenium of corpus callosum and the brainstem. The MRI findings resolved or improved upon discontinuation of metronidazole treatment. In most cases, patients recovered after discontinuation of the drug; however, rare instances of death or persisting severe neurological deficits were reported.
Differential diagnosis
Suspicion of MIE may arise when facing a patient presenting with cerebellar and brainstem deficits in close relation to metronidazole treatment. However, diagnosing MIE may not always be straightforward. A thorough history is needed to establish the relation between metronidazole treatment and the occurrence of symptoms, which in several cases were months or even years after initiation of treatment. Also, a history of exposure may not be immediately obtainable in encephalopathic patients. Our findings show that almost one-third of patients concomitantly present with polyneuropathy, making the clinical picture potentially even more complex.
The most important diagnostic findings are T2/FLAIRhyperintense lesions in the dentate nuclei, an anatomical site where lesions are otherwise rarely found, especially in isolation. In some cases, lesions of the dentate nuclei were not present initially, but occurred on re-imaging [37, 102] . Therefore, serial imaging may be indicated when diagnostic uncertainty remains.
Based on the presentation and characteristic MRI findings, we wish to highlight some of the most important differential diagnostic considerations.
Wernicke's encephalopathy is caused by deficiency of thiamine, and clinical findings include ataxia, gait instability, altered mental status and oculomotor disturbances. These patients sometimes also present with polyneuropathy, typically from alcohol abuse. The combination of alcohol abuse and poor nutrition may rarely result in cystic degeneration of the corpus callosum termed Marchiafava-Bignami disease. The clinical picture is highly variable, and may include altered mental status, seizures, and gait instability thereby mimicking MIE. Wernicke's encephalopathy and Marchiafava-Bignami disease can usually be differentiated from MIE by MRI findings. Nevertheless, assessment of nutritional status including thiamine is necessary in patients suspected for MIE, and in cases of doubt vitamin substitution is warranted. Similarly, patients suffering from Crohn's disease are also at risk of malnutrition and metronidazole is often a drug of choice when these patients develop gastrointestinal infections.
Hepatic encephalopathy is another important differential diagnosis based on symptoms, especially because of the overrepresentation of hepatic disease in our population. In some included cases, metronidazole was used to treat suspected hepatic encephalopathy complicating diagnostics even further.
Methyl bromide [119] is a gas used as a pesticide and as a methylating agent in commercial manufacturing of chemicals. Chronic methyl bromide intoxication causes central and peripheral neurological symptoms strikingly similar to MIE. The pathogenesis is most likely methylation of intracellular proteins and lipids and thereby disruption of essential metabolic processes, although there is dispute on the subject. The conjugation of methyl bromide to glutathione is believed to be protective and consequently some authors recommend treating methyl bromide poisoning with N-acetylcysteine. MRI typically shows T2/FLAIR-hyperintense lesions in the dentate nuclei, splenium of corpus callosum and the brainstem, making it an important differential diagnosis. Differentiation is based on history of exposure and elevated serum bromide.
Other types of toxic encephalopathies are relevant to consider, especially antibiotic-associated encephalopathies [3] , because patients are regularly treated with more than one antibiotic at a time. Antibiotic-associated encephalopathy is divided into three clinical pictures. Type 1 is caused by penicillin and cephalosporins and has an onset within days after initiation of treatment. Symptoms involve seizures and myoclonus and MRI is normal. Type 2 is caused by procaine penicillin, sulfonamides, fluoroquinolones, and macrolides and also has an onset within days after initiating treatment. The dominating symptom is psychosis and MRI is normal. Type 3 is caused by metronidazole. However, cases involving other 5-nitroimidazoles ornidazole [120, 121] and tinidazole [24] have been described with symptoms very similar to MIE and MRI findings including hyperintense lesions in dentate nuclei on T2 and FLAIR in all three cases.
Certain leukodystrophies, inborn errors of metabolism, lysosomal storage diseases and mitochondrial diseases can also cause T2/FLAIR-hyperintense lesions in the dentate nuclei [122, 123] . These diseases are chronic, slowly progressive and typically present in childhood. Leukodystrophies involve widespread cerebral white matter lesions and spasticity. Inborn errors of metabolism, lysosomal storage diseases and mitochondrial disease affect other organs as well, which separates these conditions from MIE. A wide screening of organ markers is therefore indicated, and specific genetic testing can in some cases be relevant, especially in children.
Other rare but important differential diagnoses include primary CNS lymphoma and progressive multifocal leukoencephalopathy (PML).
Case reports beyond the scope of this review have suggested a relationship between metronidazole and a clinical presentation dominated by acute psychosis [124] [125] [126] [127] [128] [129] . The clinical picture in these cases was highly distinct from MIE cases in this review, and the correlation has never been supported by MRI.
Treatment and prognosis
No studies have been performed concerning specific treatment of MIE in humans. If the condition is suspected, the drug must be discontinued immediately and MRI performed. Patients spontaneously begin to recover within days after drug cessation, therefore treatment is primarily symptomatic.
Comparing outcomes after discontinuation of metronidazole is complicated. Some authors simply state that the patient improved, while others conducted a long and meticulously described follow-up. Twelve patients had unfavorable outcomes, defined as death or persisting significant disability, and are summarized in Table 1 .
The six patients who expired all received a cumulative dose below the median, except a female paraplegic weighing 45 kg who continued to receive a dose of 1500 mg metronidazole once daily for 2 weeks after onset of somnolence. The remaining five patients suffered from serious premorbid conditions such as advanced cancer or organ failure. The indications for metronidazole treatment were often severe infections which persisted until death. Overall, MIE was not the primary cause of death in these five cases. However, symptoms like altered sensorium, dysarthria, and gait instability, can impair communication and ambulation and thus be a contributing factor in severely ill patients. Conversely, severe premorbid conditions may increase sensitivity to the toxic effects of metronidazole.
Five patients had persisting severe neurological deficits despite improvement and one patient remained in a vegetative state. Three of these cases had significant premorbid conditions including short bowel syndrome and primary biliary cholangitis combined with interstitial pneumonia. One patient was treated with three times the daily dose on his own initiative following chronic use for unknown duration, and another patient received a relatively high cumulative dose of 250 g. The final case was unremarkable, although the patient was elderly.
Remarkably, all six surviving patients with unfavorable outcomes had lesions in the cerebral white matter on T2/ FLAIR, DWI or ADC. This only applied to 18% (n = 24) of all cases for which MRI was available. A similar correlation did not apply to any other type of lesion. Thus, lesions of the cerebral white matter may be correlated with a worse prognosis.
Due to limitations in descriptions and follow-up, it is not possible based on our population to conclude whether polyneuropathy resolves with time. According to a recent review, most cases of metronidazole-induced polyneuropathy improve or resolve with time [5] . Nerve conduction studies generally showed an axonal sensory or sensorimotor polyneuropathy in our population.
Pathophysiology
Metronidazole easily penetrates the blood-brain barrier and achieves high concentrations in the CNS [130, 131] . Metronidazole is metabolized by the liver and excreted through urine [130] . Severe hepatic or renal disease may therefore result in buildup of metronidazole and its byproducts, possibly reflecting the high prevalence of hepatic disease and renal failure in our population.
Additionally, metronidazole crosses the placenta, illustrated by the remarkable MRI-verified case of MIE in a newborn that failed to thrive after his mother was treated for bacterial vaginosis during late pregnancy [16] .
Multiple theories have been proposed on the mechanism behind MIE, although evidence on the subject is sparse.
The clinical phenotype and neuroanatomical predilection sites in MIE bear similarities to several above-mentioned toxic, nutritional, and genetic differential diagnoses, particularly chronic methyl bromide intoxication and to some extent, Wernicke's encephalopathy. In several of these conditions, the pathogenesis may be disruption of energy-metabolism leading to deleterious cellular effects, also coined energy-deprivation syndromes. Specifically, it has been suggested that the predilection of the cerebellum, brainstem, and periventricular areas is due to particular vulnerability of these sites to disruption of energy-metabolic pathways [132] . Experimental research has been conducted with specific regard to the toxic effects of metronidazole on the CNS:
In 1973, von Rogulja et al. [133] conducted an experimental study inducing MIE in rats causing changes in gait and loss of balance. Histological examinations showed symmetrical CNS-lesions in the brainstem and cerebellar nuclei comparable to those caused by thiamine (Vitamin B 1 ) deficiency in previous experiments.
Alston and Abeles [134] elaborated on these findings in 1987 and proposed a theory of thiamine antagonism. They used an enzyme produced by a common human gut bacteria, to induce a reaction between metronidazole and thiamine. The resulting thiamine analogue showed competitive inhibition of thiamine in vitro, and thus could reduce thiamine action. In recent years, MRI studies have shown comparable brainstem lesions in patients suffering from MIE and Wernicke's encephalopathy, especially in non-alcoholic patients [135, 136] . However, lesions in the dentate nuclei were only present in four patients, and one of them had been treated with metronidazole. Furthermore, lesions in the thalami and mammillary bodies which are characteristic in Wernicke's encephalopathy, are rarely found in MIE as only 2.4% (n = 3) of our cases had thalamic lesions and none had mammillary body lesions. This difference in imaging suggests that thiamine antagonism can at most explain a part of the mechanism.
Later, Evans et al. [137] conducted a retrospective animal study on dogs, and articulated an interesting theory on the subject. The theory was based upon GABA (gamma-aminobutyric acid) being the primary inhibitory neurotransmitter of the cerebellar and vestibular systems affected by metronidazole intoxication. Furthermore, activation of GABA receptors by benzodiazepines can alleviate symptoms arising from dysfunction of these structures. They discovered that dogs treated with the benzodiazepine diazepam recovered earlier from metronidazole-induced symptoms, and hypothesized that metronidazole binds to the benzodiazepine site on GABA receptors, resulting in loss of GABAergic inhibition. This antagonism may be mediated by a structurally similar imidazole group shared by metronidazole and the benzodiazepine antidote flumazenil.
The intended bactericidal effect of metronidazole is based on an enzyme-dependent reduction of metronidazole in anaerobes, resulting in a highly reactive metabolite that binds to DNA and disrupts its function. In theory, this reaction could also occur in humans, under the right conditions. Bradley et al. [138] studied rats treated with large doses of carbon-labeled metronidazole. Autopsies showed that metronidazole had chemically reacted with RNA in the central nervous system. Rao and Mason [139] have shown that catecholamines norepinephrine and serotonin can reduce metronidazole in vitro, resulting in the formation of noxious free radicals. However, it required a very alkaline environment, making it unlikely in vivo.
MRI also provides some insights to the potential pathogenesis of MIE. In the majority of callosal and cerebral white matter lesions DWI showed correspondingly hypointense ADC, indicating true restricted diffusion as seen in cytotoxic edema. DWI lesions in the dentate nuclei and other locations showed variable ADC signals. This suggests that both cytotoxic and vasogenic edema may result from the toxic effects of metronidazole. One case [23] reported increased lactate resonance on MR spectroscopy as well as increased lactate levels in the CSF, suggesting disruption of cellular metabolism. However, these results may not be applicable to all patients since the patient had trisomy 21.
Limitations
There are some limitations to this review. The only search engine used was PubMed and language was limited to English. Furthermore, data are based upon case reports and series which contain more unknown factors than controlled studies and present a varying amount of details. Approximately one-third of cases did not mention whether the patient had previously known diseases. Treatment durations and cumulative doses often had to be approximated. Some patients were treated with other medications known to potentially cause neurological symptoms. Long-term follow-up was not necessarily conducted in cases where symptoms initially persisted.
Differences in accessibility to healthcare, dosing regimens, comorbidities and availability of MRI likely affect regional prevalences of MIE. Thus, speculations regarding genetic susceptibility are complicated. Underreporting is likely substantial, which is also illustrated by cases series with numerous patients from one medical center.
Perspectives
The awareness of MIE is increasing-the first cases of convulsive seizures due to metronidazole intoxication in humans were reported in 1978 and 50 cases of MIE (37%) have been reported since 2015. The increasing amount of publications on the topic may also express greater accessibility to MRI. Future investigations may lead to a deeper understanding of the pathophysiology and risk factors of MIE. Hopefully, future cases can also provide information regarding treatment, for example whether diazepam, thiamine or N-acetylcysteine could provide relief of symptoms.
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Conclusion
In conclusion, MIE is a credible and well-defined pathological entity applicable to most clinicians. The condition is rare but most likely underdiagnosed. The mechanisms behind the CNS toxicity of metronidazole are yet unresolved. Patients with hepatic disease and to a lesser degree renal failure are overrepresented in MIE. It is not possible to predict when patients develop symptoms based on a cumulative dose or duration of treatment. Typical clinical findings include dysarthria, gait instability, limb dyscoordination and altered mental status. Almost one-third of patients present with concomitant metronidazole-induced polyneuropathy. MRI is obligatory and will in most cases show characteristic symmetrical hyperintense lesions on T2-weighted and FLAIR sequences in the bilateral dentate nuclei, and less commonly in sites such as the splenium of the corpus callosum and midbrain. Only a relatively limited number of differential diagnoses exists. After treatment cessation, the imaging lesions improve or resolve. We did not find a correlation between cumulative doses and outcome. The prognosis is favorable when the drug is discontinued and supportive care is provided, underlining the importance of awareness and early recognition of the condition.
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